Target Therapeutics
This article was originally published in The Gray Sheet
Executive Summary
Files a patent infringement suit Nov. 9 in U.S. District Court in San Francisco against SciMed Life Systems and Cordis Endovascular Systems. The Fremont, California-based manufacturer alleges that SciMed's Venture intravascular infusion catheter and Transend guidewire and Cordis' Transit infusion catheter and Instinct steerable guidewire infringe Target's patent No. 4,739,768, "A Catheter for Guide-Wire Tracking." Patent "768 covers the principal technology in Target's FasTracker micro- catheters. The company seeks treble damages and a permanent injunction against the sale of Cordis' and SciMed's allegedly infringing products
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.